Abstract:Nicotinamide mononucleotide (NMN) is a precursor of nicotinamide adenine dinucleotide (NAD), which declines with age. Supplementation of NMN has been shown to improve blood NAD concentration. However, the optimal NMN dose remains unclear. This is a post-hoc analysis of a double-blinded clinical trial involving 80 generally healthy adults aged 40 to 65 years. The participants received a placebo or daily 300 mg, 600 mg, or 900 mg NMN for 60 days. Blood NAD concentration, blood biological age, homeostatic model assessment for insulin resistance, 6-minute walk test, and 36-item short-form survey (SF-36) were measured at baseline and after supplement. A significant dose-dependent increase in NAD concentration change (NAD ) was observed following NMN supplementation, with a large coefficient of variation (29.2-113.3%) within group. The increase in NAD was associated with an improvement in the walking distance of 6-minute walk test and the SF-36 score. The median effect dose of NAD for the 6-minute walk test and SF-36 score was 15.7 nmol/L (95% CI: 10.9-20.5 nmol/L) and 13.5 nmol/L (95% CI; 10.5-16.5 nmol/L), respectively. Because of the high interindividual variability of the NAD after NMN supplementation, monitoring NAD concentration can provide valuable insights for tailoring personalized dosage regimens and optimizing NMN utilization.

What problem does this paper attempt to address?

The main problems that this paper attempts to solve are to determine the effect of nicotinamide mononucleotide (NMN) supplements on the concentration of nicotinamide adenine dinucleotide (NAD) in the blood and to explore the optimal dosage of different dosages of NMN supplements in healthy middle - aged and elderly people. Specifically, the research focuses on the following aspects: 1. **Effect of NMN supplements on changes in blood NAD concentration**: Through a double - blind randomized controlled trial, the research evaluated the effects of different dosages (300 mg, 600 mg, 900 mg) of NMN supplements on the blood NAD concentration. The results showed that NMN supplements can significantly increase the NAD concentration in the blood, and this increase is dose - dependent. 2. **High variability in NAD concentration changes among individuals**: The research found that even within the same dosage group, there are large differences in NAD concentration changes among different individuals, indicating that the effects of NMN supplements vary significantly among individuals. 3. **Relationship between NAD concentration changes and functional outcomes and quality of life**: The research also explored the relationship between NAD concentration changes and the distance of the 6 - minute walk test and the SF - 36 quality of life score. The results showed that the increase in NAD concentration is significantly related to the increase in the distance of the 6 - minute walk test and the improvement of the SF - 36 score. 4. **Determination of the median effective dose (ED50) of NAD concentration changes for clinically significant improvement**: Through simulation analysis, the research determined the median effective dose of NAD concentration changes required to achieve clinically significant improvement (such as an increase in the distance of the 6 - minute walk test by at least 30 meters and an improvement in the SF - 36 score by at least 10 points). For the 6 - minute walk test and the SF - 36 score, they are approximately 15.7 nmol/L and 13.5 nmol/L respectively. In summary, this paper aims to provide a scientific basis for the personalized use of NMN supplements through systematic research, especially by monitoring changes in blood NAD concentration to optimize the dosage of supplements to achieve the best health effects.

Towards personalized nicotinamide mononucleotide (NMN) supplementation: nicotinamide adenine dinucleotide (NAD) concentration